About Us
Corporate Overview
Executive Leadership
Management team
Scientific Advisory Board
Board of Directors
Clinical Advisory Board
Our Science
Pipeline
Overview
AG-73305
AG-80308
AG-86893
Disease
Overview
DME
nAMD
Other Diseases
Pterygium
Dry Eye
Clinical Trial
Investor Relations
Investors
Press Release & Publications
Allgenesis In The News
Contact Us
Press Release & Publications
Filter by
Categories
Tags
Authors
Show all
All
News
All
2015
2018
2019
2020
2021
2022
2023
All
admin
allgenesis
sky
2022-06-20
Allgenesis Announces First Patient Dosed in the U.S. for the Phase 1b trial Evaluating AG-80308 for the Treatment of Dry Eye Disease
Taipei, Taiwan/June 20th, 2022 Allgenesi
[…]
2022-06-13
Allgenesis Announces First Patient Enrollment in a FIH Phase 2a Trial of AG-73305 for the Treatment of Diabetic Macular Edema
Taipei, Taiwan/June 13th, 2022 All
[…]
2022-03-31
Allgenesis Announces FDA Clearance of the IND for AG-73305 for the Treatment of Diabetic Macular Edema
Taipei, Taiwan/ March 31st, 2022 Allgene
[…]
2022-02-28
Allgenesis Receives Notice of Grant of Patent for Fusion Protein of VEGF Trap and Disintegrin in China
February 28th, 2022 Allgenesis Biotherap
[…]
